Acquisition of Proteolix (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Acquisition of Proteolix disclosures
Contingent consideration expense	$ (2,930,000)	$ (3,178,000)
Proteolix
Acquisition of Proteolix disclosures
Milestone payment based on the accelerated marketing approval of related parties, low end	0
Milestone payment based on the accelerated marketing approval of related parties, high end	365,000,000
Contingent consideration,liability	152,100,000
Contingent consideration expense	2,930,000	3,178,000
Proteolix | Second installment
Acquisition of Proteolix disclosures
Milestone payment based on the accelerated marketing approval of related parties, high end	65,000,000
Proteolix | Third installment
Acquisition of Proteolix disclosures
Milestone payment based on the accelerated marketing approval of related parties, high end	150,000,000
Proteolix | Fourth installment
Acquisition of Proteolix disclosures
Milestone payment based on the accelerated marketing approval of related parties, high end	$ 150,000,000